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Abstract: BACKGROUND: Primary resuscitation fluid to treat hemorrhagic shock remains controversial.
Use of hydroxyethyl starches raised concerns of acute kidney injury. Polyethylene-glycolated carboxyhe-
moglobin, which has carbon monoxide-releasing molecules and oxygen-carrying properties, was hypoth-
esized to sustain cortical renal microcirculatory PO2 after hemorrhagic shock and reduce kidney injury.
METHODS: Anesthetized and ventilated rats (n = 42) were subjected to pressure-controlled hemorrhagic
shock for 1 h. Renal cortical PO2 was measured in exposed kidneys using a phosphorescence quench-
ing method. Rats were randomly assigned to six groups: polyethylene-glycolated carboxyhemoglobin
320 mg · kg, 6% hydroxyethyl starch (130/0.4) in Ringer’s acetate, blood retransfusion, diluted blood
retransfusion ( 4 g · dl), nonresuscitated animals, and time control. Nitric oxide and heme oxyge-
nase 1 levels were determined in plasma. Kidney immunohistochemistry (histologic scores of neutrophil
gelatinase-associated lipocalin and tumor necrosis factor-฀) and tubular histologic damages analyses were
performed. RESULTS: Blood and diluted blood restored renal PO2 to 51 ± 5 mmHg (mean difference,
-18; 95% CI, -26 to -11; P < 0.0001) and 47 ± 5 mmHg (mean difference, -23; 95% CI, -31 to -15; P
< 0.0001), respectively, compared with 29 ± 8 mmHg for hydroxyethyl starch. No differences between
polyethylene-glycolated carboxyhemoglobin and hydroxyethyl starch were observed (33 ± 7 mmHg vs.
29 ± 8 mmHg; mean difference, -5; 95% CI, -12 to 3; P = 0.387), but significantly less volume was
administered (4.5 [3.3-6.2] vs. 8.5[7.7-11.4] ml; mean rank difference, 11.98; P = 0.387). Blood and di-
luted blood increased the plasma bioavailability of nitric oxide compared with hydroxyethyl starch (mean
rank difference, -20.97; P = 0.004; and -17.13; P = 0.029, respectively). No changes in heme oxygenase
1 levels were observed. Polyethylene-glycolated carboxyhemoglobin limited tubular histologic damages
compared with hydroxyethyl starch (mean rank difference, 60.12; P = 0.0012) with reduced neutrophil
gelatinase-associated lipocalin (mean rank difference, 84.43; P < 0.0001) and tumor necrosis factor-฀
(mean rank difference, 49.67; P = 0.026) histologic scores. CONCLUSIONS: Polyethylene-glycolated
carboxyhemoglobin resuscitation did not improve renal PO2 but limited tubular histologic damages and
neutrophil gelatinase-associated lipocalin upregulation after hemorrhage compared with hydroxyethyl
starch, whereas a lower volume was required to sustain macrocirculation.
DOI: https://doi.org/10.1097/aln.0000000000002932
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ABSTRACT
Background: Primary resuscitation fluid to treat hemorrhagic shock 
remains controversial. Use of hydroxyethyl starches raised concerns of acute 
kidney injury. Polyethylene-glycolated carboxyhemoglobin, which has carbon 
monoxide–releasing molecules and oxygen-carrying properties, was hypoth-
esized to sustain cortical renal microcirculatory PO
2
 after hemorrhagic shock 
and reduce kidney injury.
Methods: Anesthetized and ventilated rats (n = 42) were subjected to pres-
sure-controlled hemorrhagic shock for 1 h. Renal cortical PO
2
 was measured 
in exposed kidneys using a phosphorescence quenching method. Rats were 
randomly assigned to six groups: polyethylene-glycolated carboxyhemoglo-
bin 320 mg · kg−1, 6% hydroxyethyl starch (130/0.4) in Ringer’s acetate, 
blood retransfusion, diluted blood retransfusion (~4 g · dl−1), nonresuscitated 
animals, and time control. Nitric oxide and heme oxygenase 1 levels were 
determined in plasma. Kidney immunohistochemistry (histologic scores of 
neutrophil gelatinase-associated lipocalin and tumor necrosis factor-α) and 
tubular histologic damages analyses were performed.
Results: Blood and diluted blood restored renal PO
2
 to 51 ± 5 mmHg (mean 
difference, −18; 95% CI, −26 to −11; P < 0.0001) and 47 ± 5 mmHg (mean 
difference, −23; 95% CI, −31 to −15; P < 0.0001), respectively, compared 
with 29 ± 8 mmHg for hydroxyethyl starch. No differences between polyeth-
ylene-glycolated carboxyhemoglobin and hydroxyethyl starch were observed 
(33 ± 7 mmHg vs. 29 ± 8 mmHg; mean difference, −5; 95% CI, −12 to 3; 
P = 0.387), but significantly less volume was administered (4.5 [3.3–6.2] 
vs. 8.5[7.7–11.4] ml; mean rank difference, 11.98; P = 0.387). Blood and 
diluted blood increased the plasma bioavailability of nitric oxide compared 
with hydroxyethyl starch (mean rank difference, −20.97; P = 0.004; and 
−17.13; P = 0.029, respectively). No changes in heme oxygenase 1 levels 
were observed. Polyethylene-glycolated carboxyhemoglobin limited tubular 
histologic damages compared with hydroxyethyl starch (mean rank difference, 
60.12; P = 0.0012) with reduced neutrophil gelatinase-associated lipocalin 
(mean rank difference, 84.43; P < 0.0001) and tumor necrosis factor-α 
(mean rank difference, 49.67; P = 0.026) histologic scores.
Conclusions: Polyethylene-glycolated carboxyhemoglobin resuscitation did 
not improve renal PO
2
 but limited tubular histologic damages and neutrophil 
gelatinase-associated lipocalin upregulation after hemorrhage compared 
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Fluid administration is the first step of rescue therapy during severe hemorrhage or hypovolemic shock before blood 
products become available.1 However, aggressive volume fluid 
resuscitation may lead to secondary severe tissue edema and 
clinical signs of volume overload, which result in unfavorable 
outcomes.2,3 Colloidal solutions are used to sustain intravascular 
EDITOR’S PERSPECTIVE
What We Already Know about This Topic
• The optimal fluid for resuscitation of hemorrhagic shock (crystal-
loid, colloid, or hemoglobin-containing) and mitigation of acute 
kidney injury is unknown
What This Article Tells Us That Is New
• In a rat model of hemorrhagic shock comparing fluid resuscitation with 
blood, diluted blood, hydroxyethyl starch, or polyethylene-glycolated 
carboxyhemoglobin, all fluids restored urine output and creatinine 
clearance, but only blood and diluted blood improved renal PO
2
• Postresuscitation histologic renal tubular damage was increased 
compared with nonresuscitated rats but slightly less with blood, 
diluted blood, and polyethylene-glycolated carboxyhemoglobin 
compared with hydroxyethyl starch
• Restoration of circulatory hemodynamics and kidney microcircula-
tory PO
2
 was comparable with polyethylene-glycolated carboxyhe-
moglobin and balanced hydroxyethyl starch solution
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oncotic pressure and to shorten the circulatory stabilization 
time while limiting fluid administration. Hydroxyethyl starch 
solutions remain the most used synthetic colloids for vol-
ume replacement. However, no definitive evidence exists 
for outcome advantage of starches over crystalloids in vari-
ous settings, and concerns were raised for kidney function. 
Therefore, the European Medicines Agency (Amsterdam, The 
Netherlands) restricts the use of hydroxyethyl starch solutions 
across the European Union.4,5 Hyperosmotic and hypertonic 
saline fluids are also considered alternatives, but the fluids pro-
duce uncertain outcomes and possible harm.6 Therefore, crys-
talloids remain the sole resuscitation fluid for the treatment 
of hemorrhage and severe hypovolemia before blood product 
transfusion. Current resuscitation fluids of crystalloids or syn-
thetic colloids possess no oxygen-carrying capacity and may 
promote inflammation.
Acute kidney injury is one of the most frequent organ 
failures in perioperative and critically ill patients.7 The 
pathophysiology of acute kidney injury is not fully under-
stood to date, but major contributors have been identified, 
such as renal microcirculatory hypoxemia, tissue inflam-
mation, and fluid overload.8–10 The early reestablishment of 
oxygenation and kidney perfusion during hemorrhage is 
essential to limit the subsequent development of acute kid-
ney injury.9,10
Polyethylene-glycolated carboxyhemoglobin (Sanguinate, 
Prolong Pharmaceuticals, USA) is a novel agent that exhibits 
a dual action of carbon monoxide release and oxygen car-
rying and transfer.11 Carbon monoxide is poisonous at high 
concentrations because it inhibits cellular respiration and 
interacts tightly with hemoglobin to limit oxygen delivery, 
but it also produces beneficial effects at low concentrations. 
Carbon monoxide’s homeostatic effects occur via multiple 
cellular and molecular mechanisms of action, including redox 
control, antiapoptosis and antiinflammation, modulation of 
vasoactive responses (vasodilation), and modulation of the 
innate immune response.12,13 There is compelling preclinical 
data on the use of carbon monoxide as a therapeutic agent 
via carbon monoxide–releasing molecules in models of acute 
lung injury,14 sepsis,15 hemorrhagic shock,16 and ischemia and 
reperfusion injury.17 Carbon monoxide mitigated the inflam-
matory response and ischemic damage in all of these settings.
The present study hypothesized that a molecule with the 
ability to release carbon monoxide molecules to injured tis-
sues and carry oxygen to hypoxic tissue would sustain kidney 
function by increasing renal microcirculatory oxygen ten-
sion and limiting the damage of ischemia and hypoxia after 
resuscitation from hemorrhagic shock while providing a low 
volume of resuscitation fluid. The primary outcome of our 
study was improvement of cortical renal microcirculatory 
oxygen tension. Secondary outcomes included the volume 
of fluid resuscitation, macrohemodynamics, renal immuno-
histochemistry and histologic damages, acid–base status, and 
levels of plasma biomarkers of injury. We sought to compare 
the renal microcirculatory impact of polyethylene-glycolated 
carboxyhemoglobin, 6% hydroxyethyl starch balanced in 
Ringer’s acetate, and blood transfusion as resuscitation strat-
egies in a blood pressure–targeted resuscitation model of 
hemorrhagic shock in the rat.
Materials and Methods
Animals
The Animal Research Committee of the Academic Medical 
Centre of the University of Amsterdam (Amsterdam, The 
Netherlands) approved all experiments in this study (DFL 
103073). Care and handling of the animals were performed 
in accordance with the guidelines from the Institutional and 
Animal Care and Use Committees. This study and the fol-
lowing reporting adhere to the applicable Animal Research: 
Reporting of In Vivo Experiments guidelines.18 All experi-
ments were performed on male Wistar albino rats (Charles 
River, The Netherlands), aged 10 ± 3 weeks with a mean ± 
SD body weight of 320 ± 26 g, at 9:30 am (weekdays) at the 
Department of Experimental Surgery, University Medical 
Center, Amsterdam, The Netherlands.
Surgical Preparation
The rats were anesthetized using an intraperitoneal injec-
tion of a mixture of 100 mg · kg−1 ketamine (Nimatek; 
Eurovet, The Netherlands), 0.5 mg · kg−1 dexmedetomidine 
(Dexdomitor; Orion Group, Finland), and 0.05 mg · kg−1 
atropine-sulfate (Centrafarm, The Netherlands). Anesthesia 
was maintained with 50 mg · kg · h−1 ketamine. A trache-
otomy was performed. The animals were connected to a 
ventilator (Babylog 8000, Dräger, The Netherlands) and 
ventilated with tidal volumes of 6 ml · kg−1 with a posi-
tive end-expiratory pressure of 3 cm H
2
O and a fractional 
inspired oxygen tension of 0.4. A heating pad under the 
animal allowed the body temperature to be controlled and 
maintained at 37 ± 0.5°C. The end-tidal carbon dioxide 
was maintained between 35 and 42 mmHg by adjusting 
respiratory rate (CapnoMac, Datex-Ohmeda, USA).
The carotid (pressure) and femoral (for blood shedding 
and samples) arteries and jugular (anesthesia) and femoral 
(fluid resuscitation) veins were cannulated using polyeth-
ylene catheters (outer diameter, 0.9 mm; Braun, Germany). 
Fluid maintenance during surgery was sustained using 
Ringer’s acetate (Baxter, The Netherlands) administration 
at a rate of 10 ml · kg−1 ·  h−1. The left kidney was exposed 
without decapsulation and immobilized in a Lucite kidney 
cup (K. Effenberger, Germany) via a 3-cm incision in the 
left flank. Renal vessels were carefully separated to preserve 
the nerves and adrenal gland. An ultrasonic flow probe was 
placed around the left renal artery (type 0.7 RB; Transonic 
Systems Inc., USA) and connected to a flow meter (T206; 
Transonic Systems Inc., USA) to continuously measure renal 
blood flow. The left ureter was isolated, ligated, and cannu-
lated using a polyethylene catheter for urine collection. The 
animals rested for 30 min after completion of surgery (~1 h).
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experimental Protocol
The animals were randomized according to a unique code 
that was generated by an internet website (Sealed Envelope 
Ltd., 2016, simple randomization service; available at: https://
www.sealedenvelope.com/simple-randomiser/v1/, accessed 
September 17, 2016) and placed in sealed envelopes. A tech-
nician prepared the resuscitation fluid according to the gen-
erated code on the day of the experiment. The investigator 
performing the experiments was partially blinded to group 
assignment or treatment. Control and hemorrhage groups 
received no fluids. Another investigator who was blinded to 
the type of randomization performed the data analyses.
The animals underwent stabilization period (30 min) 
and were bled from the left femoral artery catheter at a 
rate of 1 ml · min−1 using a syringe pump (Harvard 33 
syringe pump; Harvard Apparatus, USA) until reaching a 
mean arterial pressure (MAP) of ~30 mmHg. This pressure 
was maintained for 1 h via reinfusing or withdrawing blood. 
Coagulation of the shed blood was prevented with the addi-
tion of 200 IU of heparin in the syringe. The animals were 
randomized into six groups: (1) polyethylene-glycolated 
carboxyhemoglobin with a maximum dosage of 320 mg · 
kg−1, (2) 6% hydroxyethyl starch (130/0.4) balanced with 
Ringer’s acetate (Volulyte, Fresenius Kabi, Germany), (3) 
diluted blood with polyethylene-glycolated carboxyhemo-
globin’s buffer (to the same hemoglobin content as poly-
ethylene-glycolated carboxyhemoglobin: 4 g · dl−1; diluted 
blood), (4) blood transfusion (blood), (5) nonresuscitated 
animals, and (6) control, in which surgery was performed 
without hemorrhage. Fluid resuscitation was divided into 
two periods of time: a rescue therapy period of 30 min (res-
cue period, 30 min after resuscitation), in which the fluid 
tested was administered alone until reaching MAP of 80 
mmHg and stopped, and a maintenance period of 30 min 
(60 min after resuscitation), in which the resuscitated groups 
all received 6% hydroxyethyl starch. This design allowed 
comparisons between groups with a similar target (fig. 1).
measurement of renal Cortical microcirculatory PO
2
An optical fiber with a tip diameter of 5 mm was placed ~1 mm 
above the exposed kidney to measure oxygenation using a 
phosphorescence lifetime technique described elsewhere.19 
Palladium(II)-meso-tetra(4-carboxyphenyl)-porphyrin at a 
concentration of ~5 mg · ml−1 was used as a phosphorescent 
dye, injected at a dose of 1.5 ml · kg−1 and excited at 530 nm. 
The phosphorescent decay time signal corresponds to the 
microcirculatory Po
2
 in the kidney, and it was continuously 
recorded and processed using software developed in LabView 
2014 (National Instruments, USA) as described previously.19 
The depth of penetration of green light and catchment depth 
were estimated to be within the renal cortex. We excluded 
any interference between palladium(II)-meso-tetra(4-car-
boxyphenyl)-porphyrin and polyethylene-glycolated car-
boxyhemoglobin (in vitro) before the in vivo experiment.
Determination of oxygen-carrying Capacity of 
Polyethylene-glycolated Carboxyhemoglobin and 
Spectrophotometric Analyses of Its Derivatives
Because polyethylene-glycolated carboxyhemoglobin 
is bound with carbon monoxide molecules, and its oxy-
gen-carrying capacity is reduced. The release of carbon 
monoxide likely increases the oxygen-carrying capacity 
of the molecule. The oxygen-binding/carrying capacity 
of polyethylene-glycolated carboxyhemoglobin was deter-
mined at 37°C under normal atmospheric conditions using 
similar previously described methods (Supplemental Digital 
Content 1, http://links.lww.com/ALN/C41). A second set 
of experiments determined the oxygen-binding/carrying 
capacity of the molecule after full saturation of polyeth-
ylene-glycolated carboxyhemoglobin in 100% oxygen (for 
2 h) to induce carbon monoxide release. However, com-
plete carbon monoxide release was not achieved.
The unknown spectrum was determined spectrophoto-
metrically in UV-visible light ranging from 500 to 650 nm 
with a 1-nm increment at 37°C (Synergy HTX, BioTek, 
Fig. 1. Design and timeline of the experiment. Control rats were subjected to the same surgery but did not undergo the hemorrhage protocol. 
Nonresuscitated hemorrhagic shock rats were observed during the same time of observation. mAP, mean arterial pressure.
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Germany) to determine the concentration of each deriv-
ative (carboxyhemoglobin, oxyhemoglobin, and deoxyhe-
moglobin) of polyethylene-glycolated carboxyhemoglobin 
in the plasma. The observed total absorption spectrum of 
each plasma sample was then compared with the known 
spectra of the different derivatives of bovine hemoglobin20 
with their absorption values. With the use of the classical 
least squares’ method (mixture of three components with 
150 wavelengths, see Supplemental Digital Content 1, 
http://links.lww.com/ALN/C41), the different concentra-
tions of each component were recovered.
The concentration of polyethylene-glycolated carboxy-
hemoglobin in the plasma was obtained after the addition 




 to 40 μl of 
plasma to convert all polyethylene-glycolated carboxyhe-
moglobin derivatives to hemiglobincyanide. The endpoint 
absorbance was read at 540 nm against a calibration curve.
measurements of Arterial blood Gas and biochemistry
Arterial blood samples (250 μl) were collected at four 
time points (fig. 1). Arterial blood gas parameters were 
determined using a blood gas analyzer (ABL80 Flex, 
Radiometer, Denmark), and total hemoglobin con-
centration, hemoglobin oxygen saturation, base excess, 





 · dl−1) was calculated considering 
the oxygen-carrying capacity of polyethylene-glyco-






















 × 0.0031, where Hb
RBC
 is the hemoglobin 
concentration in erythrocyte (g · dl−1), S is the arterial 
oxygen saturation of Hb
RBC
 or polyethylene-glyco-
lated carboxyhemoglobin, and γ is the oxygen-carrying 
capacity of Hb
RBC
 (1.34 ml O
2
 · g-1 Hb for rat blood) or 
polyethylene-glycolated carboxyhemoglobin, as previ-





 · min−1) was determined at the end of the experi-




 × renal blood flow.
Plasma creatinine and urine creatinine were measured 
using an automatic analyzer (c702, Roche Diagnostics, 
Switzerland). We established a calibration curve for creati-
nine levels before measurements to correct for a significant 
interference because of the presence of polyethylene-gly-
colated carboxyhemoglobin. Plasma osmolarity was deter-
mined using the freezing point method with an osmotic 
pressure meter (OSMOstation OM-6050, Menarini, 
Benelux, Belgium). The glomerular filtration rate was esti-
mated at the end of the experiment using the measurement 











 is the concentration of creatinine in 
urine (mmol · l−1), V is the urine volume (ml) per unit time 
of urine collection, and P
Crea
 is the concentration of creati-
nine in plasma (mmol · l−1).
Plasma Nitric oxide and Heme oxygenase 1 Levels
The samples were placed in the reducing agent vanadium 
(III) chloride (VCl
3
) in 1 mol · l−1 HCl at 90°C to reduce 
the nitrate and nitrite in the plasma samples to nitric oxide. 
The vanadium (III) chloride reagent converts nitrite, 
nitrate, and S-nitroso compounds to nitric oxide gas that 
is guided toward a nitric oxidechemiluminescence signal 
analyzer (Sievers 280i analyzer, GE Analytical Instruments, 
USA) to allow the direct detection of nitric oxide.21 Nitric 
oxide within the reaction vessel reacts with ozone to gen-
erate oxygen and excited-state nitric oxide species, and the 
decay is associated with the emission of weak near-infrared 
chemiluminescence. A sensitive photodetector detects this 
signal and converts it to millivolts. The area under the curve 
of the detected chemiluminescence (mV · s) represents the 
amount of nitrix oxide-ozone reactions in real time and 
thus the amount of bioavailable nitric oxide in the tested 
samples.
Heme oxygenase 1 constitutes an essential cytoprotec-
tive component that ameliorates hemorrhagic shock-in-
duced oxidative tissue injuries.22 Plasma heme oxygenase 
1 levels were measured at the end of the experiment using 
an enzyme-linked immunosorbent assay (ELISA) kit based 
on the sandwich assay principle (rat HMOX1/HO-1 
ELISA kit [sandwich ELISA], LS-F4085, LSBio LifeSpan 
BioSciences Inc., USA).
Immunohistochemical Analysis and Histology
The animals were euthanized at the end of the exper-
iment using 40% Euthasol (Produlab Pharma BV, The 
Netherlands). The kidneys were harvested, fixed in 4% 
formalin, and embedded in paraffin. Ten tubular areas 
(n = 10) on each slice per animal were analyzed. A mini-
mum of 40 tubules were examined per group, with n = 6/
kidney per animal minimum. The complete description of 
immunohistochemical analyses and histology are detailed 
in Supplemental Digital Content 1 (http://links.lww.
com/ALN/C41). A histologic score value for neutrophil 
gelatinase–associated lipocalin and tumor necrosis factor-α 
was derived for each sample via summing the percentages 
of cells that stained at each intensity multiplied by the 
weighted intensity of the staining (histologic score = S Pi 
[i + 1], where i is the intensity score, and Pi is the corre-
sponding percentage of the cells) under a light microscope 
at ×400 magnification. Histologic changes (brush border, 
vacuolar degeneration, cast formation, and invagination) in 
the cortex were assessed using quantitative measurements 
of tissue damage.
Statistical Analysis
The values are expressed as means ± SD when normally 
distributed (Kolmogorov–Smirnov test) or as median 
[interquartile range] otherwise. Repeated-measures two-
way ANOVA (two factors: time as a related within-animal 
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factor and group as a between-animal factor) and post hoc 
Bonferroni correction test for multiple analyses were used 
to determine intergroup and/or intragroup differences in 
hemodynamics, cortical renal Po
2
, and biochemical data. We 
reported the simple main effects of group (type of fluid) 
compared with the control and to the hydroxyethyl starch 
groups at each time point when a significant interaction 
was observed between time and group, and the simple 
main effect of time versus baseline within the same group. 
Ordinary one-way ANOVA with Bonferroni correction 
was used for the analyses of the oxygen-binding capacity of 
polyethylene-glycolated carboxyhemoglobin, renal oxygen 
delivery, ELISA heme oxygenase 1, and volume of blood 
withdrawn. Analyses of creatinine clearance, total fluid vol-
ume, plasma nitric oxide, histologic damages to the kidney, 
and tumor necrosis factor-α and neutrophil gelatinase– 
associated lipocalin histologic scores were performed using 
a Kruskal–Wallis test with Dunn correction test because 
of their non-Gaussian distribution. Outliers were evalu-
ated, but no action was necessary. Statistical analyses were 
performed using GraphPad Prism version 7.0a for Mac 
(GraphPad Software, USA). The overall significance level 
for each hypothesis was 0.05. Adjusted P values are reported 
throughout the manuscript in post hoc tests.
We assumed that the microcirculatory Po
2
 in the kid-
ney would be of 26 ± 3 mmHg (means ± SD) at 30 min 
after resuscitation of hemorrhagic shock using 6% balanced 
hydroxyethyl starch based on previous experiments lead by 
our group. Therefore, a sample size of n  =  6/group was 
needed to detect a 20% increase in kidney microcirculatory 
Po
2
 (estimated to be 31 mmHg, ∆ of 5 mmHg) associated 
with the administration of polyethylene-glycolated car-
boxyhemoglobin (compared with balanced hydroxyethyl 
starch) and provide a power (1-β) of 80% with a type I 
error rate (α) of 5% using a two-group Satterthwaite two-
sided t test.
Results
A total of 42 animals were included in the present study 
(n = 6–8/group). Eight animals were included in the poly-
ethylene-glycolated carboxyhemoglobin group, and four 
served to established reliability in the protocol. No animal 
died during the experiment. The volume of blood with-
drawn to induce hemorrhagic shock at T1 (6.7 ± 0.8 ml) was 
similar in all groups. The withdrawn volume represented 32.2 
± 4.4% of the total blood volume. The hemorrhagic shock 
produced similar alterations in hemodynamics (MAP and 
renal blood flow) and similar reductions in kidney micro-
circulatory Po
2
 associated with a metabolic acidosis and 
hyperlactatemia in all groups compared with controls (P < 
0.0001). The hemodynamic data throughout the experiment 
are presented in table 1. MAP was restored to ~80 mmHg in 
all animals that underwent resuscitation after hemorrhagic 
shock, according to the protocol. At the end of experiment, 
the renal blood flow recovered similarly to controls except 
Table 1. Systemic and renal Hemodynamics and Urine excretion
Baseline Shock
Rescue Phase  
(30 min after Resuscitation)
Maintenance  
(60 min after Resuscitation)
mAP, mmHg     
 Control 94 ± 10 81 ± 5 84 ± 6 90 ± 6
 Nonresuscitated 92 ± 5 32 ± 2* 32 ± 1* 30 ± 1*
 6% balanced hydroxyethyl starch 92 ± 10 32 ± 1* 81 ± 4 83 ± 6
 PeGylated carboxyhemoglobin 91 ± 7 32 ± 2* 76 ± 11 81 ± 3
 blood transfusion 89 ± 4 32 ± 2* 86 ± 8 87 ± 10
 Diluted blood transfusion 90 ± 6 33 ± 2* 81 ± 1 79 ± 4*
renal blood flow, ml · min−1     
 Control 9.8 ± 2.3 7.9 ± 2.6 7.4 ± 2.4 7 ± 2.4
 Nonresuscitated 10.5 ± 3.2 3.0 ± 1* 3.2 ± 1.1* 3.0 ± 1*
 6% balanced hydroxyethyl starch 9.7 ± 1.3 3.9 ± 2.4* 7.4 ± 2.4 8.4 ± 2.9
 PeGylated carboxyhemoglobin 11.6 ± 2 2.8 ± 0.5* 6.3 ± 1.2 8.3 ± 1.6
 blood transfusion 10.0 ± 1.7 2.3 ± 0.3* 5.0 ± 0.3 5.4 ± 0.5†
 Diluted blood transfusion 11.6 ± 1.2 3.1 ± 1.5* 7.0 ± 1.7 7.3 ± 1.6
Urine output, ml · h−1     
 Control 2.80 ± 0.73 2.2 ± 1.42 2.46 ± 0.94 1.87 ± 0.53
 Nonresuscitated 4.68 ± 1.8 0 ± 0‡ 0 ± 0‡ 0 ± 0‡
 6% balanced hydroxyethyl starch 2.77 ± 0.91 0 ± 0‡ 2.55 ± 0.75 3.93 ± 2.35
 PeGylated carboxyhemoglobin 4.01 ± 2.3 0 ± 0‡ 0.76 ± 0.55‡ 3.97 ± 1.43
 blood transfusion 3.29 ± 1.94 0 ± 0‡ 0.85 ± 0.52‡ 2.2 ± 1.43
 Diluted blood transfusion 4.04 ± 1.31 0 ± 0‡ 1.63 ± 1.20‡ 3.63 ± 1.75
The values are presented as means ± SD. repeated measures two-way ANovA test used with bonferroni correction to adjust for multiple comparisons.
*Adjusted P < 0.01 versus control group at the same time point. †Adjusted P < 0.05 versus 6% balanced hydroxyethyl starch group at the same time point. ‡P < 0.01 versus baseline 
value within the same group.
mAP, mean arterial pressure; PeGylated, polyethylene glycolated.
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for the blood transfusion group, which was lower than in the 
hydroxyethyl starch group (P = 0.015). The changes in acid–
base status and lactate levels differed according to the resus-
citation fluid administered (table 2). Balanced hydroxyethyl 
starch was the most efficient fluid at restoring the acid–base 
status at the end of the rescue phase compared with other 
therapies. Polyethylene-glycolated carboxyhemoglobin cor-
rected the pH, but base excess, bicarbonate levels, and lactate 
levels remained significantly higher than controls (mean dif-
ference, −1.5; 95% CI, −2.6 to −0.4; P = 0.0018; table 2).
Significant differences in urine output at baseline were 
observed between groups. Therefore, only intragroup com-
parisons were performed. Notably, urine output after the 
rescue phase in the blood transfusion group was lower than 
at baseline (mean difference, 2.44; 95% CI, 0.93 to 3.95; 
P = 0.0006), and urine output was readily restored 30 min 
after resuscitation in the hydroxyethyl starch group (mean 
difference, 0.23; 95% CI, −1.28 to 1.74; P = 0.969; table 1).
Kidney microcirculatory PO
2
 and renal Function
Figure  2 shows that hemorrhagic shock significantly 
reduced baseline renal cortical Po
2
 in all groups compared 
with baseline and controls. The mean renal cortical Po
2
 
was 13 ± 5 mmHg 60 min after hemorrhagic shock induc-
tion. Similar MAP and renal blood flow were observed 
between groups, but none of the fluid therapies restored 
renal cortical Po
2
 to levels similar to controls 30 or 60 min 
after resuscitation. Whole blood transfusion and diluted 
blood transfusion outperformed 6% balanced hydroxyethyl 
starch in increasing renal cortical Po
2
 at the end of exper-
iment to 51 ± 5 mmHg (mean difference, −19; 95% CI, 
−26 to −11; P < 0.0001) and 47 ± 5 mmHg (mean differ-
ence, −23; 95% CI, −31 to −15; P < 0.0001) versus 29 ± 
8 mmHg, respectively. However, there were no differences 
between polyethylene-glycolated carboxyhemoglobin and 
balanced hydroxyethyl starch in renal cortical Po
2
 in the 
early rescue phase (32 ± 7 mmHg vs. 27 ± 4 mmHg; mean 
difference, −6, 95% CI, −13 to 2; P =  0.209) or at the 
end of the experiment (33 ± 7 mmHg vs. 29 ± 8 mmHg; 
mean difference, −5; 95% CI, −12 to 3; P = 0.387).
Hemorrhagic shock induced acute kidney injury with 
a significant increase in plasma creatinine levels (greater 
than twofold increase of baseline values; fig. 3A) compared 
with controls (P < 0.0001). Creatinine levels remained 
higher 60 min after resuscitation compared with the control 
Table 2. Acid–base balance and Arterial Lactate Levels during experiment
Baseline Shock
Rescue Phase  
(30 min after Resuscitation)
Maintenance  
(60 min after Resuscitation)
pH     
 Control 7.41 ± 0.04 7.38 ± 0.04 7.38 ± 0.02 7.37 ± 0.01
 Nonresuscitated 7.39 ± 0.02 7.23 ± 0.02* 7.16 ± 0.05* 7.13 ± 0.05*
 6% balanced hydroxyethyl starch 7.40 ± 0.04 7.22 ± 0.05* 7.36 ± 0.03* 7.40 ± 0.04
 PeGylated carboxyhemoglobin 7.38 ± 0.02 7.20 ± 0.06* 7.29 ± 0.04*† 7.35 ± 0.02
 blood transfusion 7.40 ± 0.03 7.22 ± 0.03* 7.26 ± 0.04*† 7.33 ± 0.06
 Diluted blood transfusion 7.39 ± 0.04 7.22 ± 0.06* 7.28 ± 0.05*† 7.32 ± 0.05†
base excess, mmol · l−1)     
 Control −4.5 ± 2 −4.6 ± 1 −4.4 ± 0.9 −3.3 ± 0.6
 Nonresuscitated −2.4 ± 1.3 −12.5 ± 1.9* −15 ± 3.0* −16.6 ± 2.7*
 6% balanced hydroxyethyl starch −3.5 ± 2.0 −13.6 ± 0.8* −5.6 ± 1.4* −2.2 ± 1.4
 PeGylated carboxyhemoglobin −3.7 ± 0.8 −13.4 ± 2.3* −9.3 ± 2.0*† −4.5 ± 0.8
 blood transfusion −2.5 ± 1.7 −13.2 ± 1.4* −9.5 ± 1.3*† −6.6 ± 1.6
 Diluted blood transfusion −1.7 ± 1.9 −12.2 ± 3.8* −8.7 ± 3.1* −6.9 ± 2.5*
HCo
3
−, mmol · l −1)     
 Control 19.3 ± 1.1 19.5 ± 0.5 19.8 ± 1.1 20.8 ± 0.8
 Nonresuscitated 21.6 ± 1.8 13.8 ± 1.9* 12.7 ± 2.4*† 11.4 ± 2.2*
 6% balanced hydroxyethyl starch 20.0 ± 1.9 12.9 ± 1.1* 18.5 ± 1.4 22.1 ± 1.3
 PeGylated carboxyhemoglobin 20.1 ± 1.2 13.6 ± 1.2* 16.3 ± 1.9* 20.2 ± 0.9†
 blood transfusion 21.1 ± 1.9 13.2 ± 1.8* 16.6 ± 1* 18.3 ± 0.9†
 Diluted blood transfusion 22.4 ± 1.4 14.2 ± 2.8* 16.9 ± 2.6 18.0 ± 2.5†
Lactate−, mmol · l−1     
 Control 0.9 ± 0.2 1.4 ± 0.3 1.9 ± 0.4 2.1 ± 0.5
 Nonresuscitated 0.8 ± 0.2 5.1 ± 0.5* 5.8 ± 0.6* 7.2 ± 1.1*
 6% balanced hydroxyethyl starch 1.1 ± 0.4 5.3 ± 1.3* 3.3 ± 0.6* 2.7 ± 0.5
 PeGylated carboxyhemoglobin 0.8 ± 0.2 4.5 ± 0.7* 3.9 ± 0.8* 3.6 ± 0.8*
 blood transfusion 0.8 ± 0.1 5.1 ± 0.5* 3.0 ± 0.2 2.3 ± 0.3
 Diluted blood transfusion 0.7 ± 0.1 5.0 ± 1.4* 3.0 ± 0.8 1.9 ± 0.4
The values are presented as means ± SD. repeated measures two-way ANovA test was used with bonferroni’s correction to adjust for multiple comparisons.
*Adjusted P < 0.01 versus control group at the same time point. †Adjusted P < 0.01 versus 6% balanced hydroxyethyl starch group at the same time point.
PeGylated, polyethylene glycolated.
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rats, regardless of the therapy used (P < 0.0001). There 
were no differences regarding plasma creatinine between 
hydroxyethyl starch and polyethylene-glycolated carboxy-
hemoglobin 60 min after resuscitation (44.0 ± 6.7 µmol/l 
vs. 49.9 ± 6.4 µmol/l, respectively; mean difference, 5.9; 
95% CI, −3.0 to 14.8; P = 0.230). Conversely, the measured 




 (table  3) was calculated for all time points. 
However, the contribution of polyethylene-glycolated car-
boxyhemoglobin’s hemoglobin to arterial oxygen content 
was only considered at the last time point of the exper-
iment (60 min after resuscitation) for technical reasons. 
Therefore, we did not investigate the contribution of poly-
ethylene-glycolated carboxyhemoglobin’s hemoglobin to 
Cao
2
 30 min after resuscitation. Blood and diluted blood 
transfusions produced Cao
2
 values similar to controls. The 
Cao
2
 was superior in the polyethylene-glycolated carboxy-
hemoglobin group compared with balanced hydroxyethyl 
starch only after the rescue period (30 min; 12.5 ± 1.3 g 
· dl−1 vs. 9.4 ± 1.1 g · dl−1; mean difference, −3.0; 95% 
CI, −5.4 to −0.6; P  =  0.005). This difference was offset 
at the end of the experiment. The renal oxygen delivery 
was significantly lower in all groups at the end of experi-
ment compared with controls except in the diluted blood 
transfusion group (Supplemental Digital Content 2, http://
links.lww.com/ALN/C42).
Fluid volume
The stacked (total) fluid volume and separate volumes of 
each therapy plus balanced hydroxyethyl starch are presented 
in figure 4. The fluid volumes needed to achieve similar MAP 
targets varied significantly between groups, 8.5 (7.7 to 11.4), 
4.5 (3.3 to 6.2), 7.3 (6.4 to 7.8), and 13.2 (11.9 to 15.35) 
ml, for the balanced hydroxyethyl starch, polyethylene-gly-
colated carboxyhemoglobin, blood transfusion, and diluted 
blood transfusion groups, respectively (P < 0.0002). The 
polyethylene-glycolated carboxyhemoglobin group required 
significantly less volume than balanced hydroxyethyl starch 
(mean rank difference, −11.98; P = 0.011) to achieve similar 
MAP and renal cortical Po
2
. No additional volume of bal-
anced hydroxyethyl starch was required in the diluted blood 
transfusion group to maintain MAP over the observation 
time of the experiment. However, this latter group required 
the largest amount of fluid administration.
Fate of Polyethylene-glycolated Carboxyhemoglobin
Polyethylene-glycolated carboxyhemoglobin partially 
released its carbon monoxide molecules after injection in 
the cardiovascular system (table 3). The percentage of car-
boxyhemoglobin decreased from ~85% measured in vitro 
(manufacturer data) to 23.6 ± 9% (P < 0.0001; as deter-

































































Fig. 2. renal cortical microcirculatory PO
2
 during the experiment. For the sake of clarity, only significant differences were shown at the 
end of the experiment. repeated measures two-way ANovA test was used with bonferroni correction to adjust for multiple comparisons. 
*Adjusted P < 0.005 versus control group. #Adjusted P < 0.05 compared with 6% balanced hydroxyethyl starch at the same time point. The 
data are presented as means ± SD (n = 8 for PeG-carboxyhemoglobin group and n = 6/group for other groups). HeS-rA, 6% hydroxyethyl 
starch balanced in ringer acetate; PeGylated, polyethylene glycolated.
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The oxygen-binding capacity of polyethylene-glyco-
lated carboxyhemoglobin in vitro was determined to be 
0.29 ± 0.09 ml O
2
 · g−1 of hemoglobin (seven measure-
ments) in its original form. This oxygen-binding capacity 
increased significantly after full oxygenation of the mole-
cule to induce carbon monoxide release, reaching 0.92 ± 
0.02 ml O
2
 · g−1 of hemoglobin (P < 0.0001).
Nitric oxide and Heme oxygenase 1 in Plasma
The administration of polyethylene-glycolated carboxy-
hemoglobin did not result in a decrease in plasma nitric 
oxide concentrations, excluding a nitric oxide-scavenging 
effect. Plasma nitric oxide levels were higher in the blood 
transfusion, diluted blood transfusion, and nonresusci-
tated hemorrhagic shock groups compared with balanced 
hydroxyethyl starch (P < 0.05). However, there was no 
significant difference between the control and balanced 
hydroxyethyl starch or polyethylene-glycolated carboxy-
hemoglobin groups (Supplemental Digital Content 2A, 
http://links.lww.com/ALN/C42). Blood and diluted 
blood increased the bioavailability of NO in the plasma 
compared with balanced hydroxyethyl starch (mean rank 
difference, −20.97; P = 0.004; and mean rank difference, 
−17.13; P = 0.029, respectively).
CO is produced via the heme oxygenase 1 pathway. 



























































































































































Fig. 3. Time course of changes in plasma creatinine (A) and creatinine clearance at the end of the experiment (B). (A) repeated measures 
two-way ANovA test was used with bonferroni correction to adjust for multiple comparisons. *Adjusted P < 0.001 versus control group. 
#Adjusted P < 0.05 compared with 6% balanced hydroxyethyl starch at the same time point. The data are presented as means ± SD. (B) 
Kruskal–Wallis test with Dunn posttest was used. *Adjusted P < 0.0001 compared with control group. The data are presented as medians 
[interquartile range] (n = 8 for PeG-carboxyhemoglobin group and n = 6/group for other groups). PeGylated, polyethylene glycolated.
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1 in the plasma. We were unable to detect any significant 
changes in plasma heme oxygenase 1 between groups, but 
there was a trend toward higher heme oxygenase 1 levels in 
the blood transfusion group (Supplemental Digital Content 
2B, http://links.lww.com/ALN/C42).
Kidney Immunohistochemistry and Histology
Figure  5 depicts the tumor necrosis factor-α (fig.  5A) 
and neutrophil gelatinase–associated lipocalin (fig.  5B) 
histologic scores in the kidney. Hemorrhagic shock 
produced a significant increase in neutrophil gelati-
nase–associated lipocalin histologic score compared with 
control rats (270 [210 to 300] vs. 225 [197.5 to 251]; 
mean rank difference, −46; P = 0.006, respectively). Only 
polyethylene-glycolated carboxyhemoglobin and blood 
transfusion prevented the alterations in neutrophil gelati-
nase–associated lipocalin histologic score after hemor-
rhagic shock and outperformed fluid resuscitation with 
balanced hydroxyethyl starch (P < 0.0005). Consistently, 
the damage scores in kidney (brush border loss, vacu-
olization, and luminal casts) were markedly decreased in 
the polyethylene-glycolated carboxyhemoglobin, diluted 
blood transfusion, and blood transfusion groups (4 [3.3 to 
4.3], 4 [3.7 to 4.7], and 3.7 [3.3 to 4], respectively) com-
pared with balanced hydroxyethyl starch (5 [4.7 to 5]; P < 
0.001) but remained significantly higher than the controls 
(P < 0.001; fig. 5C).
Table 3. Hemoglobin Levels, Arterial oxygen Content, and Fractions of PeGylated Carboxyhemoglobin’s Derivatives
Baseline Shock
Rescue Phase (30 min after 
Resuscitation)
Maintenance (60 min after 
Resuscitation)
Total hemoglobin concentration, g · dl−1     
 Control 14.4 ± 0.9 14.5 ± 0.5 14.3 ± 0.8 13.0 ± 0.3
 Nonresuscitated 15.1 ± 0.9 10.5 ± 2.0* 10.3 ± 1.2*† 9.3 ± 0.7*†
 6% balanced hydroxyethyl starch 14.8 ± 1.5 9.7 ± 1.0* 6.6 ± 0.8* 5.5 ± 0.5*
 PeGylated carboxyhemoglobin 15.6 ± 0.9 11.2 ± 1.0 8.6 ± 0.9 7 ± 1
 blood transfusion 15.3 ± 0.5 9.9 ± 0.8 13.5 ± 1.3 12.4 ± 0.9
 Diluted blood transfusion 14.8 ± 0.2 10.1 ± 0.7 11.0 ± 0.6 10.9 ± 0.2
Hematocrit, %     
 Control 44 ± 3 45 ± 1 43 ± 3 40 ± 1
 Nonresuscitated 46 ± 3 32 ± 6* 32 ± 4*† 29 ± 2*†
 6% balanced hydroxyethyl starch 45 ± 5 30 ± 3* 21 ± 2* 17 ± 2*
 PeGylated carboxyhemoglobin 48 ± 3 35 ± 3 28 ± 3 22 ± 3
 blood transfusion 47 ± 1 31 ± 3 41 ±4 38 ± 3
 Diluted blood transfusion 45 ± 0.5 31 ± 2 34 ± 1.7 34 ± 0.7
PeGylated carboxyhemoglobin and derivatives     
 Plasma PeGylated carboxyhemoglobin concentration, g · dl−1   ND 0.6 ± 0.1





 · dl−1     
 Control 19.8 ± 1.2 20.1 ± 0.6 19.8 ± 1 18.1 ± 0.4
 Nonresuscitated 20.8 ± 1.2 14.7 ± 2.7* 14.5 ± 1.6*† 13.1 ± 0.9*†
 6% balanced hydroxyethyl starch 20.4 ± 2.10 13.6 ± 1.40* 9.5 ± 1.10* 8.0 ± 0.7*
 PeGylated carboxyhemoglobin 21.6 ± 1.1 15.7 ± 1.2 13 ± 1.3 10.4 ± 1.5
 blood transfusion 21.1 ± 0.6 13.9 ± 1.1 18.7 ± 1.7 17.2 ± 1.2
 Diluted blood transfusion 20.4 ± 0.2 14.2 ± 1 15.3 ± 0.8 15.3 ± 0.3
The values are presented as means ± SD. repeated measures two-way ANovA test was used with bonferroni correction to adjust for multiple comparisons.
*Adjusted P < 0.01 versus control group at the same time point. †Adjusted P < 0.01 versus 6% balanced hydroxyethyl starch group at the same time point.
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Fig. 4. Total volume of fluid administered in each group. The 
volumes are stacked for the sake of clarity. The height of the 
stacked bins represents the total volume administered. The 
total volumes (rescue therapy + maintenance) were compared 
between groups. #Adjusted P < 0.05 compared with 6% bal-
anced hydroxyethyl starch. Kruskal–Wallis test with Dunn 
posttest was used. The data are presented as median [interquar-
tile range] (n = 8 for PeG-carboxyhemoglobin group and n = 6/
group for other groups). PeGylated, polyethylene glycolated.
Copyright © 2019, the American Society of Anesthesiologists, Inc. Unauthorized reproduction of this article is prohibited.
Guerci et al. Anesthesiology 2019; 131:1110–24 1119
Polyethylene-glycolated Carboxyhemoglobin and Shock
Fig. 5. Kidney immunochemistry and tubular histologic damage scores. (Left panels) The histologic scores of tumor necrosis factor-α (A) 
and neutrophil gelatinase-associated lipocalin (B) are presented (see Supplemental Digital Content 1, http://links.lww.com/ALN/C41, for addi-
tional information). Tubular histologic damage graph (C) was drawn by calculating mean of damages of tubular brush border loss, presence 
of luminal cast and vacuoles. (Right panels) observation of the corresponding histologic images are shown at magnification ×400. The scale 
bar is 50 µm. (A) Kidney sections were incubated overnight at 4°C with rabbit polyclonal tumor necrosis factor-α (1:100; Abcam 6671) or (B) 
incubated for 1 h at room temperature with Lipocalin 2 antibody (neurophil gelatinase-associated lipocalin, 1/150; Abcam 41105). (C) The 
kidney sections were stained with periodic acid–Schiff reagent and hematoxyline to depict tubular damage defined as loss of brush border, 
vacuolar degeneration, and cast formation. *Adjusted P < 0.05 compared with control group. #Adjusted P < 0.05 compared with 6% balanced 
hydroxyethyl starch. Kruskal–Wallis test with Dunn’s posttest was used. A minimum of 40 tubules were examined per group, with n = 6/
kidney per animal minimum. The data are presented as the median [interquartile range]. PeGylated, polyethylene glycolated.
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Discussion
The present study demonstrated that low-volume rescue 
therapy with polyethylene-glycolated carboxyhemoglobin 
provided efficient restoration of the macrohemodynam-
ics and maintained a similar kidney microcirculatory Po
2
 
compared with synthetic balanced hydroxyethyl starch after 
resuscitation of pressure-controlled hemorrhagic shock in a 
rodent model. Polyethylene-glycolated carboxyhemoglobin 
also modulated tubular damages in the kidney, which was 
associated with a mitigated expression of neutrophil gelati-
nase–associated lipocalin, because of its embedded carbon 
monoxide molecules. Polyethylene-glycolated carboxyhe-
moglobin may blunt the risk for acute kidney injury in this 
setting. The small increase in oxygen-carrying capacity pro-
vided by this molecule did not affect kidney tissue oxygen-
ation or improve lactate or creatinine clearance, but the low 
volume administered sustained urine output and produced 
very stable hemodynamic conditions for 60 min after hem-
orrhagic shock. We also demonstrated that diluted blood 
transfusion at the same level as polyethylene-glycolated car-
boxyhemoglobin provided significantly higher renal corti-
cal Po
2
 in the kidney but required markedly more volume 
to reach the targeted MAP.
Low-volume strategies were considered for decades to 
limit aggressive fluid resuscitation using large uncontrolled 
fluid boluses that increased bleeding, hemodilution, coagu-
lopathy, hemodynamic decompensation, fluid overload, and 
excess in mortality.1,2,23 Our group already published several 
studies on fluid resuscitation after hemorrhagic shock com-
paring crystalloids with colloids, balanced or unbalanced, 
and their consequences on renal cortical Po
2
.24–26 Balanced 
hydroxyethyl starch solution was found more efficient at 
restoring macrohemodynamics and renal cortical Po
2
 than 
crystalloids. In the present study, we sought to evaluate an 
alternative colloid in the context of ongoing controversies 
about hydroxyethyl starch use. The European Medicines 
Agency recently issued several restrictions on the use of 
hydroxyethyl starch solutions in different clinical settings 
across the European Union.5 Hydroxyethyl starch solutions 
are contraindicated in patients with renal impairment and 
should be administered to manage hemorrhage only when 
crystalloids alone are not considered sufficient. Therefore, 
new fluid therapies that outperform crystalloids and com-
pete with the latest synthetic colloid solutions are desired to 
improve and sustain volume status to promptly restore blood 
pressure and flow in the context of hemorrhage. However, 
blood product transfusions remain the gold standard treat-
ment of hemorrhage, but this treatment is not always readily 
available. Transfusion thresholds have been raised during the 
last decade with the implementation of restrictive transfu-
sion strategies,27,28 and fewer patients are likely to receive 
blood transfusions in the perioperative setting.
Previous generations of hemoglobin-based oxygen car-
riers failed in clinical practice primarily because of major 
side effects, such as hypertension and myocardial injury, that 
were overlooked in preclinical models.29,30 These effects 
were presumably related to the extravasation of tetram-
eric hemoglobin and nitric oxide-scavenging effects. The 
formulation of hemoglobin-based oxygen carriers has 
changed to comply with more physiologic prerequisites. 
Polyethylene-glycolated carboxyhemoglobin provides 
a larger expansion volume than balanced hydroxyethyl 
starch partially because of its oncotic effect.11 The increase 
in MAP was likely due to the PEGylation process of the 
carboxyhemoglobin rather than a nitric oxide-scavenging 
effect. Polyethylene-glycolated carboxyhemoglobin infu-
sion produced similar plasma nitric oxide levels as blood 
transfusion in our experiment. However, the administra-
tion of hydroxyethyl starch alone as a resuscitation fluid 
significantly decreased the bioavailability of nitric oxide. 
This result suggests a decreased shear stress–mediated nitric 
oxide release from the endothelium.31
Our group previously demonstrated that a low volume of 
diaspirin–cross-linked hemoglobin restored epicardial and gut 
serosal and mucosal microvascular oxygenation.32,33 Similarly, 
diaspirin–cross-linked hemoglobin restored pancreatic func-
tional capillary density in a rodent model of hemorrhagic 
shock.34 However, increasing the dose of diaspirin–cross-linked 
hemoglobin produced two main consequences: hyperoxia in 
the gut serosa and mucosae and severe hypertension. The lat-
ter effect was caused by vasoconstriction via the inhibition 
of nitric oxide. Similarly, the extensive literature on bovine 
hemoglobin–based oxygen carrier (HBOC-201, Hemopure, 
HbO
2
 Therapeutics LLC, USA) reported improvements in 
tissue oxygenation and macrohemodynamics with induced 
vasoconstriction.35 Little data on hemoglobin-based oxygen 
carriers and kidney oxygenation and function are available. 
Polyethylene-glycolated carboxyhemoglobin should not be 
regarded as a hemoglobin-based oxygen carrier per se, but 
more as a colloid with additional beneficial effects. Our exper-
iment highlighted that polyethylene-glycolated carboxy-
hemoglobin cannot compete with blood transfusion (even 
diluted at the same hemoglobin concentration) in terms of 
quality of oxygen-carrying capacity and delivery to hypoxic 
tissue. In contrast, polyethylene-glycolated carboxyhemoglo-
bin may be an interesting alternative when blood is not an 
option or in cases of delayed blood transfusion. First, the P
50
 
is lower than the one of whole blood (8 to 16 mmHg vs. 26 
to 30 mmHg, respectively),11 which impedes oxygen release 
to moderately hypoxic tissue. Second, we demonstrated that 
(1) the oxygen-binding capacity of native polyethylene- 
glycolated carboxyhemoglobin was significantly lower than 
rat (or human) hemoglobin oxygen-binding capacity even 
after carbon monoxide release and (2) the concentration of 
polyethylene-glycolated carboxyhemoglobin in the plasma 
was too low to expect any significant increase in oxygen 
delivery compared with whole blood. To test whether poly-
ethylene-glycolated carboxyhemoglobin can release more 
oxygen, its P
50
 could be theoretically altered by the use of 
RSR13 (2-[4-[[(3, 5-dimethylanilino)carbonyl]methyl]
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phenoxyl]-2-methylproprionic acid),36 a synthetic allosteric 
modifier of oxygen–hemoglobin affinity that increases oxygen 
release (rightward shift of oxygen-hemoglobin dissociation 
curve) to tissue by allosterically stabilizing deoxyhemoglobin. 
However, two limits have to be considered: (1) RSR13 will 
also alter the P
50
 of native hemoglobin, and (2) it could exac-
erbate acute renal dysfunction.36,37
The renal damage was mitigated with the use of poly-
ethylene-glycolated carboxyhemoglobin compared with 
the administration of hydroxyethyl starch alone. These 
effects may be attributed to carbon monoxide release. 
Previous studies demonstrated possible anti-inflammatory 
effects of carbon monoxide mediated via heme oxygenase 1 
activation.38 Nassour et al.16 demonstrated that carbon mon-
oxide-releasing molecules protected against hemorrhagic 
shock and resuscitation-induced organ injury and inflam-
mation in a similar rodent model of hemorrhagic shock. 
However, the carbon monoxide-releasing molecules used 
could not carry oxygen, which highlights the central role 
of carbon monoxide and heme oxygenase 1 in ischemia and 
reperfusion injury after hemorrhage.
The off-loading of carbon monoxide molecules from 
polyethylene-glycolated carboxyhemoglobin is not instan-
taneous. Approximately 23% of polyethylene-glycolated 
carboxyhemoglobin remained saturated with carbon mon-
oxide 60 min after the start of resuscitation in our study. 
Vandegriff et al.39 demonstrated that the percentage of 
carboxyhemoglobin of coboxyhemoglobin maleimide-ac-
tivated poly(ethylene) glycol (another polyethylene-glyco-
lated carboxyhemoglobin) decreased to 20 to 25% 30 min 
after mixing coboxyhemoglobin maleimide-activated 
poly(ethylene) glycol with erythrocyte in vitro which is sim-
ilar to our observations. In contrast, Zhang et al.40 observed 
different results in an in vivo top-load rodent model. Whole 
blood and plasma gas analyses revealed a low percentage 
(5 to 7%) of carboxyhemoglobin 1 and 3 min after poly-
ethylene-glycolated carboxyhemoglobin injection, which 
suggests a rapid exchange of carbon monoxide between 
polyethylene-glycolated carboxyhemoglobin and native 
erythrocyte.40 Overall, these results demonstrated a disas-
sociation of carbon monoxide molecules from polyeth-
ylene-glycolated carboxyhemoglobin, which subsequently 
re-equilibrates with native erythrocyte. The remaining 
polyethylene-glycolated hemoglobin (without carbon 
monoxide) binds oxygen or may be oxidized in the context 
of hemorrhagic shock. However, whether this chemical 
process persists after 60 min is not known.
Parrish et al.41 previously brought evidence that the 
cell-impermeant polyethylene glycol–20 kDa significantly 
affected colloid pressure and improved survival in low vol-
ume resuscitation hemorrhagic shock models. However, 
the effects of the administration of this polyethylene gly-
col–20 kDa on the kidney were not assessed. Polyethylene-
glycolated carboxyhemoglobin provides additional benefits 
with its ability to release carbon monoxide molecules and 
oxygen-binding capacity.
Limitations
First, we focused only on the golden hour after resuscitation 
after hemorrhagic shock, and long-term results on the use 
of polyethylene-glycolated carboxyhemoglobin therefore 
cannot be anticipated. Second, lactate and creatinine levels 
were higher in the polyethylene-glycolated carboxyhemo-
globin group after 1 h because of low-volume resuscitation 
even when the preset target of resuscitation, namely MAP, 
was reached. The changes in creatinine clearance may not 
be reflected at 1 h. However, there is evidence that low-vol-
ume resuscitation may improve survival, although it may 
delay the correction of biologic parameters.42 The delay in 
correction of biologic parameters is unlikely to be related to 
carbon monoxide toxicity because of the very small amount 
released. However, we cannot exclude a direct toxicity of 
polyethylene-glycolated hemoglobin. Third, it may be diffi-
cult to distinguish the cytoprotective effects of carbon mon-
oxide from the colloidal effect of polyethylene-glycolated 
carboxyhemoglobin that restores blood flood and pressure. 
Nevertheless, previous works demonstrated that the admin-
istration of hemoglobin-based oxygen carrier in the carboxy 
state protected against focal ischemia.39,40 Fourth, 6% balanced 
hydroxyethyl starch was used in each group to maintain the 
targeted MAP after the rescue phase, and it may be consid-
ered a bias. However, this study design provided a more real-
istic approach. The use of a crystalloid or colloid to maintain 
blood volume in a context of hemorrhage occurs daily in 
clinical practice. Fifth, the observation time was set at 1 h after 
resuscitation, which may be short. However, the present study 
sought to specifically assess the effects of polyethylene-glyco-
lated carboxyhemoglobin on renal oxygenation and function 
in the early phase of resuscitation after hemorrhagic shock. A 
survival benefit of polyethylene-glycolated carboxyhemoglo-
bin was demonstrated previously.43 Further research is war-
ranted to determine the mid- to long-term effects on the 
kidney. An observation period of 3 to 7 days of recovery after 
resuscitation of hemorrhagic shock with polyethylene-glyco-
lated carboxyhemoglobin would be relevant in this context.
Conclusions
Polyethylene-glycolated carboxyhemoglobin exhibited 
interesting properties for the resuscitation of hemorrhagic 
shock, especially because of the limited volume adminis-
tered. Biomarkers of shock were not corrected as quickly 
as expected, but there is evidence that polyethylene-glyco-
lated carboxyhemoglobin’s dual action protects the kidney 
against ischemia and reperfusion damages after resuscita-
tion through its carbon monoxide molecules and sustained 
urine output, which partially contribute to an increase 
in the oxygen delivery to tissues during the first hour of 
resuscitation. Further research on colloidal solutions should 
be intensified to provide the anesthesiologists and inten-
sive care unit physicians an interesting option for meeting 
unmet clinical needs. Finally, whether polyethylene-gly-
colated carboxyhemoglobin exhibits long-term protective 
Copyright © 2019, the American Society of Anesthesiologists, Inc. Unauthorized reproduction of this article is prohibited.
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effects on the kidney without adverse effects on the other 
organs should be determined in future studies.
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From Fixing Photos to Fixing Cyanide Poisoning: 
Herschel's “Hypo” or Sodium Thiosulfate
In 1819, a soon-to-be-knighted John Herschel (1792 to 1871) discovered that hyposulfite of soda could “fix” 
or make photographic images permanent by dissolving away unexposed and otherwise insoluble silver salts. 
This British genius soon coined terms for his astronomical or botanical images as “negatives” or “positives” 
and for the art as “photography.” Even after it was renamed sodium thiosulfate, hyposulfite of soda retained 
photographers’ nickname for it: “hypo.” An antidote for cyanide poisoning, sodium thiosulfate was supplied in 
ampoules to physicians by Eli Lilly (above) and other pharmaceutical firms. Eventually, an editor-in-chief of 
Anesthesiology, Dr. John Michenfelder, would help popularize the antidotal availability of sodium thiosulfate 
for treating cyanide toxicity resulting from overdoses of antihypertensive infusions of sodium nitroprusside. 
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